Bio-Path warns of going concern doubt, seeks financing; director resigns

BIO-PATH HOLDINGS, INC.

Director Douglas Morris resigned effective Nov 13, 2025; resignation received Nov 4.
Company seeking financing to fund turnaround; plans to update finance team, engage new PCAOB auditors, hire investment bankers to review biotech portfolio for sale/partnership/M&A.
Warns substantial doubt about ability to continue as going concern if capital raise fails; notes risk of delisting from OTC Markets.
No specifics on financing amount or timeline; strategic review of portfolio and M&A pursuits announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.